Oto Revenue and Competitors

London, UK

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Oto's estimated annual revenue is currently $4.3M per year.(i)
  • Oto's estimated revenue per employee is $189,000

Employee Data

  • Oto has 23 Employees.(i)
  • Oto grew their employee count by -21% last year.

Oto's People

NameTitleEmail/Phone
1
Co-FounderReveal Email/Phone
2
Software EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$28.1M10412%N/AN/A
#2
$35.9M1331%N/AN/A
#3
$74.3M2505%N/AN/A
#4
N/A0N/AN/AN/A
#5
$24M89-19%£8.2MN/A
#6
$8.6M40-9%N/AN/A
#7
$15.3M63-14%N/AN/A
#8
$182.3M5409%N/AN/A
#9
$182.3M54014%N/AN/A
#10
$148.5M4406%N/AN/A
Add Company

What Is Oto?

Oto builds digital therapeutics for tinnitus. There are 390 million people with intrusive tinnitus around the world. Our mission to help them, by providing science-based therapy, that is accessible to all.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$4.3M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Oto News

2022-04-17 - Otonomy Reports Positive Top-Line Results from Phase 2a ...

Clinical benefit again observed for OTO-413 versus placebo for ... the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.

2022-04-17 - Alabama Football: Henry To'oto'o's 2022 preseason player ...

He will be a tarting linebacker for the Crimson Tide to open up the 2022 season. Henry To'oto'o's Photo Gallery. Syndication: Tuscaloosa News.

2022-04-17 - Otonomy Reports Positive Top-Line Results from Phase 2a ...

Clinical benefit again observed for OTO-413 versus placebo for ... the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.

2022-04-17 - Alabama Football: Henry To'oto'o's 2022 preseason player ...

He will be a tarting linebacker for the Crimson Tide to open up the 2022 season. Henry To'oto'o's Photo Gallery. Syndication: Tuscaloosa News.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.3M2310%N/A
#2
$1.6M23-39%N/A
#3
$2.3M23-4%N/A
#4
$1.9M230%N/A
#5
$5.2M23-12%N/A